JPS5920647B2 - 注射剤 - Google Patents
注射剤Info
- Publication number
- JPS5920647B2 JPS5920647B2 JP51118875A JP11887576A JPS5920647B2 JP S5920647 B2 JPS5920647 B2 JP S5920647B2 JP 51118875 A JP51118875 A JP 51118875A JP 11887576 A JP11887576 A JP 11887576A JP S5920647 B2 JPS5920647 B2 JP S5920647B2
- Authority
- JP
- Japan
- Prior art keywords
- injection
- trh
- salt
- sugar alcohol
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000007924 injection Substances 0.000 title claims description 34
- 238000002347 injection Methods 0.000 title claims description 34
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims description 21
- 150000005846 sugar alcohols Chemical class 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 15
- 102100032251 Pro-thyrotropin-releasing hormone Human genes 0.000 description 20
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 20
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 20
- 235000002639 sodium chloride Nutrition 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 229940095064 tartrate Drugs 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical compound OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000022540 Consciousness disease Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical compound NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 description 1
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 101100341529 Oryza sativa subsp. japonica ITPK2 gene Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- -1 organic acid salt Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/066—TRH, thyroliberin, thyrotropin releasing hormone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP51118875A JPS5920647B2 (ja) | 1976-10-01 | 1976-10-01 | 注射剤 |
| US05/835,815 US4167563A (en) | 1976-10-01 | 1977-09-22 | TRH Solution |
| AU29071/77A AU509037B2 (en) | 1976-10-01 | 1977-09-23 | Trh solution |
| CA287,638A CA1092024A (en) | 1976-10-01 | 1977-09-27 | Trh solution |
| DE2743586A DE2743586C2 (de) | 1976-10-01 | 1977-09-28 | Injizierbare Lösung, die L-Pyroglutamyl-L-histidyl-L-prolinamid oder ein physiologisch unbedenkliches Salz hiervon enthält |
| NLAANVRAGE7710693,A NL188928C (nl) | 1976-10-01 | 1977-09-29 | Werkwijze ter bereiding van een injecteerbare waterige oplossing, die l-pyroglutamyl-l-histidyl-l-prolinamide of een fysiologisch aanvaardbaar zout hiervan bevat. |
| FR7729569A FR2366019A1 (fr) | 1976-10-01 | 1977-09-30 | Solution injectable de l-pyroglutamyl-l-histidyl -l-prolinamide |
| GB40719/77A GB1592336A (en) | 1976-10-01 | 1977-09-30 | Trh solution |
| BE181375A BE859277A (fr) | 1976-10-01 | 1977-09-30 | Solution injectable de l-pyroglutamyl-l-histidyl-l-prolinamide et sa preparation |
| HK278/84A HK27884A (en) | 1976-10-01 | 1984-03-22 | Trh solution |
| MY267/85A MY8500267A (en) | 1976-10-01 | 1985-12-30 | Trh solution |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP51118875A JPS5920647B2 (ja) | 1976-10-01 | 1976-10-01 | 注射剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5344616A JPS5344616A (en) | 1978-04-21 |
| JPS5920647B2 true JPS5920647B2 (ja) | 1984-05-15 |
Family
ID=14747271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51118875A Expired JPS5920647B2 (ja) | 1976-10-01 | 1976-10-01 | 注射剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4167563A (en:Method) |
| JP (1) | JPS5920647B2 (en:Method) |
| AU (1) | AU509037B2 (en:Method) |
| BE (1) | BE859277A (en:Method) |
| CA (1) | CA1092024A (en:Method) |
| DE (1) | DE2743586C2 (en:Method) |
| FR (1) | FR2366019A1 (en:Method) |
| GB (1) | GB1592336A (en:Method) |
| HK (1) | HK27884A (en:Method) |
| MY (1) | MY8500267A (en:Method) |
| NL (1) | NL188928C (en:Method) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58167516A (ja) * | 1982-03-29 | 1983-10-03 | Daigo Eiyou Kagaku Kk | 糖、アミノ酸、電解質輸液の製造法 |
| US4493828A (en) * | 1982-07-26 | 1985-01-15 | Merck & Co., Inc. | Use of thyrotropin releasing hormone and related peptides as poultry growth promotants |
| JPS60190711A (ja) * | 1984-03-09 | 1985-09-28 | Tokyo Tanabe Co Ltd | プロトポルフイリン類注射用製剤 |
| US4608365A (en) * | 1984-03-30 | 1986-08-26 | University Of Southern California | Treatment of neurologic functions |
| US4797388A (en) * | 1984-05-21 | 1989-01-10 | Cetus Corporation | Pharmaceutical compositions with galactitol as carrier |
| NL8701143A (nl) * | 1986-05-27 | 1987-12-16 | Sandoz Ag | Farmaceutische preparaten. |
| CA2199734A1 (en) * | 1994-09-12 | 1996-03-21 | Fraser Aird | Corticotropin release inhibiting factor and methods of using same |
| US6039956A (en) * | 1994-09-12 | 2000-03-21 | Pennsylvania, Trustees Of The University Of, The | Corticotropin release inhibiting factor and methods of using same for treating behavioral symptoms in an anxiety disorder |
| EP1336410A4 (en) * | 2000-08-04 | 2005-10-12 | Chugai Pharmaceutical Co Ltd | PROTEIN INJECTION PREPARATIONS |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE266415C (en:Method) * | ||||
| JPS5121050B1 (en:Method) | 1962-04-07 | 1976-06-30 | ||
| GB1062898A (en) * | 1963-06-14 | 1967-03-22 | Evans Medical Ltd | Pharmaceutical compositions containing protamines |
| IL30448A (en) * | 1967-08-02 | 1972-06-28 | Diagnostic Data Inc | Protein metal chelate composition stabilized with saccharide,and preparation thereof |
| FR2221128A2 (en) * | 1973-03-13 | 1974-10-11 | Fabre Sa Pierre | Aspirin - polyol compsns. - contg. inositol, ribitol or glucuronic acid - free from ulcerogenic activity |
| FR2221127A2 (en) * | 1973-03-13 | 1974-10-11 | Fabre Sa Pierre | Corticoid or pyrazolone compsns. - contg. a natural polyol-free from Cerogenic activity |
| US3865934A (en) * | 1973-04-02 | 1975-02-11 | Abbott Lab | Method of enhancing memory and learning |
| US3873709A (en) * | 1974-02-19 | 1975-03-25 | Abbott Lab | Method of treating psychosis |
| DE2410821A1 (de) * | 1974-03-07 | 1975-09-18 | Hoechst Ag | Pharmazeutische kombinationspraeparate mit psychotroper wirkung und verfahren zu ihrer herstellung |
| US3959248A (en) * | 1974-04-03 | 1976-05-25 | Merck & Co., Inc. | Analogs of thyrotropin-releasing hormone |
| GB1523598A (en) * | 1975-03-08 | 1978-09-06 | Reckitt & Colmann Prod Ltd | Tripeptides |
| JPS51118841A (en) * | 1975-04-03 | 1976-10-19 | Takeda Chem Ind Ltd | A drug for improving and treating clouding of consciousness |
-
1976
- 1976-10-01 JP JP51118875A patent/JPS5920647B2/ja not_active Expired
-
1977
- 1977-09-22 US US05/835,815 patent/US4167563A/en not_active Expired - Lifetime
- 1977-09-23 AU AU29071/77A patent/AU509037B2/en not_active Expired
- 1977-09-27 CA CA287,638A patent/CA1092024A/en not_active Expired
- 1977-09-28 DE DE2743586A patent/DE2743586C2/de not_active Expired
- 1977-09-29 NL NLAANVRAGE7710693,A patent/NL188928C/xx not_active IP Right Cessation
- 1977-09-30 FR FR7729569A patent/FR2366019A1/fr active Granted
- 1977-09-30 GB GB40719/77A patent/GB1592336A/en not_active Expired
- 1977-09-30 BE BE181375A patent/BE859277A/xx not_active IP Right Cessation
-
1984
- 1984-03-22 HK HK278/84A patent/HK27884A/xx not_active IP Right Cessation
-
1985
- 1985-12-30 MY MY267/85A patent/MY8500267A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5344616A (en) | 1978-04-21 |
| NL188928B (nl) | 1992-06-16 |
| AU2907177A (en) | 1979-03-29 |
| GB1592336A (en) | 1981-07-08 |
| NL7710693A (nl) | 1978-04-04 |
| US4167563A (en) | 1979-09-11 |
| AU509037B2 (en) | 1980-04-17 |
| BE859277A (fr) | 1978-03-30 |
| DE2743586C2 (de) | 1987-01-29 |
| HK27884A (en) | 1984-03-30 |
| FR2366019A1 (fr) | 1978-04-28 |
| CA1092024A (en) | 1980-12-23 |
| FR2366019B1 (en:Method) | 1981-02-06 |
| NL188928C (nl) | 1992-11-16 |
| MY8500267A (en) | 1985-12-31 |
| DE2743586A1 (de) | 1978-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Price | Effects of carbon dioxide on the cardiovascular system | |
| CA2244209C (en) | Improved concentrated injection and infusion solutions for intravenous administration | |
| US2556567A (en) | Douche composition | |
| BRPI0518173B1 (pt) | composiçôes oftálmicas | |
| JP2013536874A (ja) | 鼻腔噴霧剤 | |
| BR112020019192A2 (pt) | Composição farmacêutica que compreende ácido deoxicólico | |
| JPS5920647B2 (ja) | 注射剤 | |
| RU2002103315A (ru) | Офтальмическая композиция, содержащая кетотифен | |
| PT1965787E (pt) | Tratamento de xerostomia com um antioxidante que contém enxofre | |
| JP6629877B2 (ja) | 鼻粘膜投与用医薬組成物 | |
| JP2009510087A (ja) | 安定アスコルビン酸組成物 | |
| ES2220056T3 (es) | Solucion oftalmica que comprende glicogeno. | |
| EP0392888A1 (fr) | Compositions thérapeutiques pour le traitement ou la prévention du ronflement | |
| JP2563336B2 (ja) | 角膜透過促進点眼剤 | |
| Polk Jr | Treatment of severe burns with aqueous silver nitrate (0.5 percent) | |
| KR102172439B1 (ko) | 지방 분해용 조성물 및 이를 포함하는 주사제 조성물 | |
| JP7296316B2 (ja) | リサミングリーンの点眼液、及び眼科学におけるその使用 | |
| JP2671381B2 (ja) | 点眼剤 | |
| JP5019923B2 (ja) | プラノプロフェン含有医薬組成物 | |
| JP3214116B2 (ja) | 術中輸液製剤 | |
| JPS6011684B2 (ja) | 注射剤 | |
| Rocha et al. | Hyperosmolarity enhances smooth muscle contractile responses to phenylephrine and partially impairs nitric oxide production in the rat tail artery | |
| Travell | Influence of pH on absorption of nicotine from urinary bladder and subcutaneous tissues | |
| JPS6340166B2 (en:Method) | ||
| HUP0202098A2 (en) | Use of 2-aminotetralin derivatives for production of pharmaceutical composition for the therapy of glaucoma |